Novavax, Inc. has completed its rolling regulatory submission to the UK regulator, the MHRA, for the approval of its COVID-19 vaccine NVX-CoV2373. If approved, it will join the four other coronavirus vaccines already on the market.
The filing is noteworthy for two reasons, one being that it is the first for a protein-based coronavirus vaccine in the UK, the US company noted